The European Federation of Pharmaceutical Industries and a Associations has issued a joint statement with EURODIS Rare Diseases Europe on access to treatment for people with rare diseases. In the statement, the organizations put forward their shared goal to reduce disparities in access to treatments for rare diseases. In addition, the two introduced a conceptual framework to price drugs to countries based on their economies, called Equity-Based Tiered Pricing (EBTB).
According to Emily Kimber, “A number of proposals are also included, supported by both EFPIA and EURORDIS, that aim to improve pricing and reimbursement processes and Health Technology Assessment (HTA), at both EU and member state level.”
To learn more, click here.
(Source: PM Live, June 15th, 2022)